Boston Scientific Corporation (BSX)

NYSE: BSX · USD

$46.1

+0.55 (+1.2%)· Recorded snapshot

Coverage state: Latest published research available

Market snapshot recorded 2026-07-29 02:00 UTC. Latest published research analyzed 2026-05-12 · stale · sources unverified. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate a fresh BSX analysis

The published report stays available while a new owner-requested analysis runs.

StockMarketAgent Research · Analyzed 2026-05-12

Our latest published analysis: BSX rated Strong Buy

BSX is rated Strong Buy at $54.10 versus the reconciled fair value midpoint of $70.39, with +30.11% upside/downside and 88/100 confidence tied to the accepted valuation synthesis.

Fair value (mid)

$70.4 / share

$55.9 – $85.1

Upside to FV

+30.1%

from $46.1

Confidence

88/100

Moat

9/10

Market cap	$80.4B
Revenue (ttm)	20.6B
Net income (ttm)	3.6B
EPS (ttm)	$2.39
Shares out	1.5B
P/E (trailing)	19.3x
P/E (forward)	14.4x
Volume	26,876,276
Beta	0.58
Price target	$72.3	+57.0%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 20.6B
Net income (ttm): 3.6B
EPS (ttm): $2.39
P/E (trailing): 19.3x
P/E (forward): 14.4x
Market cap: $80.4B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$11.89B	$12.68B	$14.24B	$16.75B	$20.07B	+14.0%
Gross profit	$8.18B	$8.73B	$9.90B	$11.49B	$13.85B	+14.1%
Operating income	$1.82B	$2.03B	$2.42B	$3.00B	$3.97B	+21.5%
Net income	$1.04B	$698.0M	$1.59B	$1.85B	$2.90B	+29.2%
EPS (diluted)	$0.69	$0.45	$1.07	$1.25	$1.94	+29.5%
EBITDA	$2.51B	$2.75B	$3.45B	$3.86B	$5.10B	+19.4%
R&D	$1.20B	$1.32B	$1.41B	$1.62B	$2.05B	+14.3%
SG&A	$4.36B	$4.52B	$5.19B	$5.98B	$6.89B	+12.1%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	41.0x	11.0x	104.3%	+6.8%	+58.6%	Sell
ABNB	Airbnb Inc.	90.8B	37.5x	7.2x	15.9%	+29.9%	+7.6%	Hold
ADBE	Adobe Inc.	104.7B	15.1x	4.2x	60.7%	+11.9%	-28.7%	Strong Buy
ABBV	AbbVie Inc.	465.2B	129.7x	7.4x	14.4%	+4.6%	+44.0%	Hold
ABT	Abbott Laboratories	186.9B	34.9x	4.0x	7.9%	+3.0%	-12.5%	Strong Buy
AMGN	Amgen Inc.	209.2B	27.0x	5.6x	19.1%	+8.1%	+32.5%	Strong Buy

All BSX indicators

Market & fundamental data

Available fields

283

Groups with data

Currency

USD

Showing 283 of 283 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000885725
Company name	Boston Scientific Corporation
Country	United States
Country code	US
Cusip	101137107
Employees	59,000
Employees Change	6,000%
Employees Change Percent	11.32
Enterprise value	$78B
Exchange	NYSE
Financial currency	USD
First seen	2026-05-09
In Index	SP500
Industry	Medical Devices
Industry PE	42.14
Industry PE Fwd	19.74
IPO Date	1992-05-18
Isin	US1011371077
Last refreshed	2026-07-29
Market cap	$68.5B
Market cap category	Large-Cap
Price	$46.06
Price currency	USD
Rev Per Employee	349,389.83x
Sector	Healthcare
Sector PE	45.6
Sector PE Fwd	24.3
Sic	3841
Symbol	BSX
Website	https://www.bostonscientific.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	5.21%
EV Earnings	21.89x
EV Sales Forward	3.56x
EV/EBIT	20.57x
EV/EBITDA	15.04x
EV/FCF	22.46x
EV/Sales	3.79x
FCF yield	5.08%
Forward P/E	13.41x
P/B ratio	2.65x
P/E ratio	19.27x
P/S ratio	3.32x
PE Ratio10 Y	88.45x
PE Ratio3 Y	60.97x
PE Ratio5 Y	69.72x
PEG ratio	0.9x
PS Forward	3.12x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	18.4%
EBITDA Margin	25.16%
FCF margin	16.86%
Gross margin	68.94%
Gross Profit	$14.2B
Gross Profit Growth	18.28%
Gross Profit Growth Q	12.67%
Gross Profit Growth3 Y	16.63%
Gross Profit Growth5 Y	15.5%
Net Income	$3.6B
Net Income Growth	75.44%
Net Income Growth Q	98.96%
Net Income Growth Quarters	6%
Net Income Growth Years	3%
Net Income Growth3 Y	61.52%
Net Income Growth5 Y	77.73%
Pretax Margin	18.16%
Profit Margin	17.29%
Profit Per Employee	$60,424
Profitable Quarters	$22
Profitable Years	5
ROA	6.07
Roa5y	4.61
ROCE	9.53
ROE	14.66
Roe5y	8.1
ROIC	11.13
Roic5y	7.52

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	6.89%
Cagr15y	13.7%
Cagr1y	-56.63%
Cagr20y	4.88%
Cagr3y	-4.35%
Cagr5y	0.24%
EPS Growth	74.39
EPS Growth Q	100
EPS Growth Quarters	6
EPS Growth Years	3
EPS Growth3 Y	59.39
EPS Growth5 Y	76.04
FCF Growth	15.3%
FCF Growth Q	-51.7%
FCF Growth3 Y	42.69%
FCF Growth5 Y	18.01%
OCF Growth	13.88%
OCF Growth Q	-35.68%
OCF Growth10 Y	16.87%
OCF Growth3 Y	34.76%
OCF Growth5 Y	18.36%
Revenue Growth	17.43x
Revenue Growth Q	11.58x
Revenue Growth Quarters	21x
Revenue Growth Years	5x
Revenue Growth3 Y	16.48x
Revenue Growth5 Y	15.29x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.49
Assets	$44.4B
Cash	$1.5B
Current Assets	$8.7B
Current Liabilities	$4.6B
Debt	$11B
Debt EBITDA	$2.13
Debt Equity	$0.42
Debt FCF	$3.17
Equity	$26.1B
Interest Coverage	10.62
Liabilities	$18.2B
Long Term Assets	$35.7B
Long Term Liabilities	$13.7B
Net Cash	$-9.6B
Net Cash By Market Cap	$-13.99
Net Debt EBITDA	$1.85
Net Debt Equity	$0.37
Net Debt FCF	$2.76
Tangible Book Value	$268M
Tangible Book Value Per Share	$0.18
WACC	6.82

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.9
Inventory Turnover	2.14
Net Working Capital	$2.7B
Quick ratio	0.98
Working Capital	$4.1B
Working Capital Turnover	$6.45

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.42%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	94.68%
1Y total return	-56.6%
200-day SMA	73.92
3Y total return	-12.5%
50-day SMA	47.15
50-day SMA vs 200-day SMA	50under200
5Y total return	1.21%
All Time High	109.5
All Time High Change	-57.94%
All Time High Date	2025-09-09
All Time Low	2.34
All Time Low Change	1,865.02%
All Time Low Date	1993-10-07
ATR	1.49
Beta	0.58
Beta1y	0.25
Beta2y	0.67
Ch YTD	-51.69
High	47.16
High52	109.5
High52 Date	2025-09-09
High52ch	-57.94%
Low	45.81
Low52	42.2
Low52 Date	2026-07-15
Low52ch	9.15%
Ma50ch	-2.3%
Premarket Change Percent	1.8
Premarket Price	$46.33
Premarket Volume	81,915
Price vs 200-day SMA	-37.69%
RSI	54.83
RSI Monthly	27.58
RSI Weekly	27.72
Sharpe ratio	-2.26x
Sortino ratio	-2.49
Total Return	-0.42%
Tr YTD	-51.69
Tr15y	586.44%
Tr1m	4.14%
Tr1w	6.65%
Tr3m	-23.17%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	31
Analyst Count Top	11
Analyst Price Target Top	$77.63
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$0.83
Earnings EPS Estimate Growth	10.67
Earnings Revenue Estimate	5,376,244,600x
Earnings Revenue Estimate Growth	6.23x
Operating Income	$4.1B
Operating Income Growth	26.49
Operating Income Growth Q	14.41
Operating Income Growth3 Y	24.38
Operating Income Growth5 Y	26.87
Operating margin	19.92
Price target	$72.31
Price Target Change	$56.99
Price Target Change Top	$68.54

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1,482,350,479%
Float Percent	99.73%
Net Borrowing	-997,000,000
Shares Insiders	0.16%
Shares Institutions	92.35%
Shares Out	1,486,355,179
Shares Qo Q	-0.05%
Shares Yo Y	0.42%
Short Float	1.91%
Short Ratio	1.42
Short Shares	1.9

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$3.2B
Adjusted OCF	4,033,000,000
Average Volume	18,658,593.95x
Bv Per Share	17.4
CAPEX	$-866M
Ch10y	94.68
Ch15y	586.4
Ch1m	4.14
Ch1w	6.65
Ch1y	-56.6
Ch20y	159.5
Ch3m	-23.17
Ch3y	-12.5
Ch5y	1.21
Ch6m	-50.8
Change	1.21%
Change From Open	-0.78
Close	45.51
Days Gap	2
Depreciation Amortization	1,394,000,000
Dollar Volume	1,237,921,272.6
Earnings Date	2026-07-29
Earnings Time	bmo
EBIT	$3.8B
EBITDA	$5.2B
EPS	$2.39
F Score	7
FCF	$3.5B
FCF EV Yield	4.45x
FCF Per Share	$2.34
Financing CF	-888,000,000
Fiscal Year End	December
Founded	1,979
Goodwill	18,536,000,000
Graham Number	30.5902
Graham Upside	-33.59
Income Tax	$184M
Investing CF	-2,731,000,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-07-29
Last Report Date	2026-03-31
Last Split Date	2003-11-06
Last Split Type	Forward
Last10k Filing Date	2026-02-17
Lynch Fair Value	$59.75
Lynch Upside	29.72
Ma150	65.7
Ma150ch	-29.89%
Ma20	44.18
Ma20ch	4.25%
Net CF	724,000,000
Next Earnings Date	2026-10-21
Open	46.42
Optionable	Yes
P FCF Ratio	19.7
P FCF Ratio SBC	21.62
P OCF Ratio	15.77
P OCF Ratio SBC	16.98
Position In Range	18.52
Post Close	46.06
Postmarket Change Percent	0.96
Postmarket Price	$46.5
Ppne	4,610,000,000
Pre Close	45.51
Price Date	2026-07-28
Price EBITDA	$13.2
Ptbv Ratio	255.5
Relative Volume	1.44x
Revenue	20,614,000,000x
SBC By Revenue	1.49x
Share Based Comp	308,000,000
Tax By Revenue	0.89x
Tax Rate	4.92%
Tr20y	159.49%
Tr6m	-50.8%
Us State	Massachusetts
Views	615
Volume	26,876,276
Z Score	5.77

Frequently asked questions

About this BSX report

What is the latest published BSX stock rating?

Boston Scientific Corporation is shown with strong buy in the latest published report, analyzed 2026-05-12. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full BSX analysis?

The full latest published report, analyzed 2026-05-12, lives at /stocks/BSX/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair-value range is used for BSX?

The latest published report analyzed 2026-05-12 frames BSX around USD 56 to USD 85. This is a dated valuation range, not a live market price; check the valuation, sensitivity, and bear-case tabs before making a decision.

How often is the BSX page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-12). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

Boston Scientific Corporation (BSX)

Coverage state: Latest published research available

Generate a fresh BSX analysis

Our latest published analysis: BSX rated Strong Buy

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · BSX

Valuation

Profitability

Balance sheet

Trading

Position sizing & entry playbook

Next earnings

Sector percentile context

All BSX indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on BSX

Frequently asked questions